Brian Wolpin
Director of the · Mass General Brigham
Credentials: · · · ·
History
- Present
Gastrointestinal Cancer Center · Mass General Brigham
- Present
- 2004–2006
- 1997–2001
Research
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Nature · 2017 · 1,640 citations
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021 · 1,081 citations
Acquired Resistance to KRASG12C Inhibition in Cancer
New England Journal of Medicine · 2021 · 1,038 citations
- CF
105 papers
77 papers
51 papers
47 papers · 1 as a fellow
- SC
47 papers
44 papers
44 papers · 2 as a fellow
41 papers
Grants
- 2016–2027
Altered Metabolism and Machine Learning for Pancreatic Cancer Early Detection
National Cancer Institute · U01
Contact PI · $8.7M · Dana-Farber Cancer Inst
- 1997–2026
Dana-Farber/Harvard Cancer Center
National Cancer Institute · P30
Project lead · $220.2K · Dana-Farber Cancer Inst
- 2007–2025
Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer
National Cancer Institute · P50
Contact PI · $3.4M · Dana-Farber Cancer Inst
- 2009–2014
Cohort Study of Biochemical and Genetic Risk Factors for Pancreatic Cancer
National Cancer Institute · K07
Contact PI · $889.6K · Dana-Farber Cancer Inst
Clinical trials
- 2011–2014
Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
- 2010–2015
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Principal investigator · Completed · Phase 1, Phase 2
Dana-Farber Cancer Institute
OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas
Principal investigator · Withdrawn · Phase 1, Phase 2
Dana-Farber Cancer Institute
- 2024–2029